stockrowJazz Pharmaceuticals PLC
JAZZ Healthcare Biotechnology
Jazz Pharmaceuticals PLC’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 4.88% from fiscal 2024.
- Revenue
- +10.4%
- EPS
- −280.5%
- Free cash flow
- −60.4%
- Total debt
- +3.88%
Quarter to September 2026, against a year earlier
Follow JAZZ
Alert me
Jazz Pharmaceuticals PLC (JAZZ) Current ratio
Jazz Pharmaceuticals PLC's current ratio at the end of the quarter to 30 September 2026 was 1.8×, down 0.0× from fiscal 2025 (1.9×). Over the past ten years it has ranged from 1.9× (fiscal 2025) to 5.5× (fiscal 2015) — the current reading is the lowest in ten years. That is below the Biotechnology industry median of 4.9× and below the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 1.9× | (58.32%) |
| FY2024 | 4.5× | 99.37% |
| FY2023 | 2.2× | (19.95%) |
| FY2022 | 2.8× | (13.45%) |
| FY2021 | 3.2× | (25.71%) |
| FY2020 | 4.3× | (2.89%) |
| FY2019 | 4.5× | 25.22% |
| FY2018 | 3.6× | 8.43% |
| FY2017 | 3.3× | 13.35% |
| FY2016 | 2.9× | (47.63%) |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 1.8× | 2.38% |
| Jun 2026 | 1.8× | (12.80%) |
| Mar 2026 | 2.0× | 9.81% |
| Dec 2025 | 1.9× | 12.48% |
| 43 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| KYMR Kymera Therapeutics, Inc. compare | 11.1× |
| SMMT Summit Therapeutics PLC compare | 7.0× |
| TECH Bio-Techne Corp compare | 4.5× |
| HALO Halozyme Therapeutics, Inc. compare | 3.9× |
| EXEL Exelixis, Inc. compare | 3.2× |
| ASND Ascendis Pharma A/S compare | 3.0× |
| BMRN BioMarin Pharmaceutical Inc. compare | 2.4× |
| BBIO BridgeBio Pharma, Inc. compare | 2.1× |
| JAZZ Jazz Pharmaceuticals PLC | 1.8× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on JAZZ
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement